Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ResMed Inc. filings document operating results, governance actions, capital returns and securities registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and fiscal-year financial results, record board-declared cash dividends and describe the treatment of NYSE common stock and ASX CHESS Depositary Interests in dividend payments.
The company’s regulatory record also covers board composition, director elections, executive officer transitions, compensation arrangements and amendments to the ResMed Inc. 2009 Incentive Award Plan. Proxy materials provide stockholder voting matters, executive compensation disclosure and corporate-governance information for the medical technology company’s public-company structure.
ResMed (RMD) Form 144 notice: An insider intends to sell 2,575 shares of ResMed common stock on the NYSE through Fidelity Brokerage Services. The filing lists an aggregate market value of $739,289.14 and shows 146,414,839 shares outstanding. The securities were reported as acquired in connection with an option granted on 11/16/2023 and listed as acquired and scheduled for sale on 08/18/2025. The transaction is shown as a cash sale through the named broker. The filer states they are not aware of undisclosed material adverse information about the issuer.
ResMed Chief Executive Officer Michael J. Farrell exercised stock options and sold shares on 08/07/2025 under a Rule 10b5-1 plan adopted on October 31, 2024. He exercised 8,009 options at a $101.64 exercise price, acquiring 8,009 common shares, and sold those 8,009 shares in multiple trades at a weighted-average price of $279.4829 (individual trades ranged $277.76–$282.66). After the transactions Farrell’s direct beneficial ownership is reported as 455,503 shares, and he also holds 24,029 derivative securities; 2,090 shares are held indirectly via the Lisette and Michael Farrell Family Trust.
Filing: Form 4 filed by Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), signed 08/04/2025.
On 08/01/2025 Mr. Sandercock reported two non-derivative transactions and one derivative entry. He acquired 2,000 shares of ResMed common stock under a Rule 10b5-1 plan at $101.64 (reported beneficial ownership after this line: 86,283 shares). He disposed of 3,000 shares at $281.90 (reported beneficial ownership after this line: 83,283 shares). Separately, he reported 2,000 option-related derivative securities with an exercise price of $101.64, exercisable from 11/11/2019 and expiring 11/14/2025, leaving 6,000 derivative securities beneficially owned following the report.
Disclosures: The stock transactions were executed under a Rule 10b5-1 plan adopted February 19, 2025. Options vest 1/3 per year.
ResMed Inc. (RMD) Form 4: Global General Counsel & Secretary Michael J. Rider reported a modest open-market sale of company stock.
- Transaction: On 01 Aug 2025 he sold 50 common shares at $281.90 each, generating roughly $14.1k in gross proceeds. The sale was carried out under a pre-arranged Rule 10b5-1 plan adopted 28 Feb 2025.
- Post-sale holdings: Rider now directly owns 8,486 shares; no derivative positions were reported.
The divestiture represents an immaterial decrease in the executive’s stake and an insignificant fraction of ResMed’s total float, suggesting limited market impact. Because the trade was executed under a 10b5-1 plan, timing-related information asymmetry concerns are mitigated. Investors may view the filing as routine but should track subsequent insider activity for trend changes.
ResMed Inc. (RMD) – Form 144 filing: Insider Michael Rider has notified the SEC of his intent to sell up to 50 common shares through Fidelity Brokerage on or about 01 Aug 2025 on the NYSE. The shares carry an estimated market value of $14,095 and originate from restricted-stock vesting on 11 Nov 2021 that was received as compensation.
The filing also discloses earlier open-market sales by Rider in the last three months: 41 shares on 02 Jun 2025 for $9,994.98 and 66 shares on 01 Jul 2025 for $16,961.34. In total, Rider has sold or proposes to sell 157 shares in the period, compared with the company’s 146,627,399 shares outstanding, resulting in a de-minimis ownership impact (<0.001%). No other material terms, lock-ups, or 10b5-1 plan details are provided in the notice.